Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

  • STATUS
    Recruiting
  • End date
    Jun 25, 2024
  • participants needed
    26
  • sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Send
Updated on 25 January 2021
See if I qualify
cancer
hysterectomy
carcinoma
gemcitabine
carcinoma in situ
docetaxel
luteinizing hormone
bladder cancer
invasive bladder cancer
transurethral resection
bladder tumor
intravesical bcg
bcg vaccine
intravesical bcg therapy

Summary

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to providing initial efficacy data, this study will provide safety and long-term efficacy data on the combination regimen studied. A tolerable safety profile and demonstrated efficacy would support a potential, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

Details
Condition urinary tract neoplasm, bladder cancer, bladder disorder, Transitional Cell Carcinoma of the Bladder, Urothelial Cancer, Urothelial Carcinoma Bladder, Bladder Disorders, Bladder Carcinoma, Urologic Cancer, transitional cell carcinoma of bladder, carcinoma of the bladder, bladder tumor
Treatment docetaxel, Gemcitabine
Clinical Study IdentifierNCT04386746
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last Modified on25 January 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Bladder Carcinoma or Bladder Disorders or Urothelial Carcinoma Bladder or bladder disorder or urinary tract neoplasm or bladder cancer or Urologic Can...?
Do you have any of these conditions: bladder disorder or Urothelial Carcinoma Bladder or Bladder Disorders or Urologic Cancer or Urothelial Cancer or bladder cancer or carcinoma of the bl...?
Histologically confirmed intermediate or high-risk non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on TURBT obtained within 90 days of registration defined according to modified EORTC risk criteria summarized as follows
Low-risk tumors: Initial or recurrent tumor > 12 months after resection with all of the following
Solitary tumor
Low-grade
< 3 cm
No carcinoma in situ (CIS)
Intermediate-risk tumors: All tumors not defined in the two adjacent categories (between the category of low- and high-risk)
High-risk tumors: Any of the following
T1 tumor
High-grade
CIS
Multiple and recurrent and large (> 3 cm) Ta low-grade tumors (all conditions must be met for this point of Ta low-grade tumors)
Note #1: Low-risk tumors as defined above are not eligible
Note #2: Mixed histologies are permitted, provided a component of urothelial carcinoma is present
Note #3: All patients with high-grade T1 (HGT1) should undergo a restaging TURBT
Eastern Cooperative Oncology Group (ECOG) (WHO) performance status 0, 1, or 2
Age 18 years old at time of consent
Evidence of post-menopausal status or negative urinary or serum pregnancy test or female pre-menopausal patients is required. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply
Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
Women 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
Subjects who give a written informed consent obtained according to local guidelines

Exclusion Criteria

Subjects with muscle-invasive (i.e. T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 90 days prior to study registration. The required radiographic imaging
includes
Abdomen/Pelvis - CT scan
Chest - chest x-ray or CT scan
Subjects with concurrent upper urinary tract (i.e. ureter, renal pelvis) urothelial carcinoma of any stage
Note: Subjects with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post-treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no evidence of residual disease are eligible
Subjects with another active second malignancy with an estimated overall survival from the second malignancy of < 12 months. Subjects with another second active malignancy that are deemed to have an estimated overall survival of >12 months are eligible
Subjects who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
Subjects who have had radiotherapy 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
Pregnant or breast-feeding women
Subjects unwilling or unable to comply with the protocol
Patients with prior systemic gemcitabine or docetaxel use for a non-bladder malignancy may enroll and receive treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
hysterectomy
carcinoma
gemcitabine
carcinoma in situ
docetaxel
luteinizing hormone
bladder cancer
invasive bladder cancer
transurethral resection
bladder tumor
intravesical bcg
bcg vaccine
intravesical bcg therapy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note